Novo Nordisk have brought in Ludovic Helfgott from fellow big pharma player AstraZeneca, to take up the position of EVP of biopharm.
The company’s biopharm business includes its haemophilia portfolio and human growth hormone franchise. In the role, Helfgott will report directly to Lars Fruergaard Jørgensen, CEO of Novo Nordisk.
Up until present, Helfgott has remained at AstraZeneca for the duration of his pharma career.. He held various positions, across a range of geographical areas, including at AstraZeneca Italia and AstraZeneca España. He most recently occupied the position of global VP of cardiovascular, renal and metabolism at AstraZeneca.
Commenting on his new role, he said, “I'm excited to join Novo Nordisk and look forward to working with the biopharm team on improving lives for people with haemophilia, growth disorders and other serious chronic diseases”.
Helfgott will replace Jesper Brandgaard in the role, after the latter decided to retire after a 20-year career at Novo Nordisk that ended with him being EVP of biopharm and legal affairs.
Jørgensen said of Brandgaard’s career at the company: “I would […] like to thank Jesper Brandgaard for his significant contributions to Novo Nordisk, both as our CFO for many years and most recently as head of biopharm, where he has taken important steps towards bringing the business back on a growth track.”